Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000069.xml
Download PDF
Semin Liver Dis 2004; 24: 63-70
DOI: 10.1055/s-2004-828680
DOI: 10.1055/s-2004-828680
HBV Infection in Patients With End-Stage Renal Disease
Further Information
Publication History
Publication Date:
11 June 2004 (online)
Controlling the spread of hepatitis B virus (HBV) infection in dialysis units has been one of major triumphs in the management of end-stage renal disease. However, HBV incidence and prevalence rates remain high in dialysis patients in less-developed countries, and HBV within dialysis units continues to spread in the industrialized world. Overall response rates to HBV vaccination are lower in dialysis patients than in the nondialysis population. Lamivudine is effective in the treatment of HBV infection in the dialysis setting. Presence of hepatitis B surface antigen (HbsAg) has a negative impact on patient survival after renal transplantation. Several issues remain unanswered with regard to the management of HBV infection in dialysis patients, including the management of lamivudine resistance and the optimal timing and duration of antiviral therapy. Liver biopsy prior to renal transplantation is crucial in order to identify and exclude patients with advanced fibrosis or even cirrhosis.
KEYWORDS
Hepatitis B virus - renal disease - therapy - lamivudine
REFERENCES
- 1 Snydman D R, Bryan J A, Hanson B. Hemodialysis-associated hepatitis in the United States-1972. J Infect Dis. 1975; 132 109-113
- 2 Centers for Disease Control and Prevention .Control Measures for Hepatitis Type B in Dialysis Centers. Viral Hepatitis Investigations and Control Series 1977
MissingFormLabel
- 3 Alter M J, Favero M S, Maynard J E. Impact of infection control strategies on the incidence of dialysis-associated hepatitis in the United States. J Infect Dis. 1986; 153 1149-1151
- 4 Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings. MMWR Morb Mortal Wkly Rep. 1988; 37 377-382
- 5 Kellerman S, Alter M J. Preventing hepatitis B and hepatitis C virus infections in end-stage renal disease patients: back to basics. Hepatology. 1999; 29 291-293
- 6 Tokars J I, Frank M, Alter M J, Arduino M J. National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial. 2002; 15 162-171
- 7 Burdick R A, Bragg-Gresham J L, Woods J D et al.. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2003; 63 2222-2229
- 8 Centers for Disease Control and Prevention . Outbreaks of hepatitis B virus infection among hemodialysis patients-California, Nebraska, and Texas, 1994. JAMA. 1996; 275 1394-1395
- 9 Hutin Y J, Goldstein S T, Varma J K et al.. An outbreak of hospital-acquired hepatitis B virus infection among patients receiving chronic hemodialysis. Infect Control Hosp Epidemiol. 1999; 20 731-735
- 10 Fabrizi F, Lunghi G, Finazzi S et al.. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis. 2001; 38 1009-1015
- 11 Fabrizi F, Mangano S, Alongi G et al.. Influence of hepatitis B virus viremia upon serum aminotransferase activity in dialysis population. Int J Artif Organs. 2003; 26 1048-1055
- 12 Locatelli F, Marcelli D, Conte F et al.. Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto. Nephrol Dial Transplant. 2000; 15(Suppl 5) 69-80
- 13 Maisonneuve P, Agodoa L, Gellert R et al.. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999; 354 93-99
- 14 Josselson J, Kyser B A, Weir M R, Sadler J H. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am J Kidney Dis. 1987; 9 456-461
- 15 Marcelli D, Stannard D, Conte F et al.. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int. 1996; 50 1013-1018
- 16 Fabrizi F, Martin P. Hepatitis B vaccine and dialysis: current issues. Int J Artif Organs. 2001; 24 683-694
- 17 Rangel M C, Coronado V G, Euler G L, Strikas R A. Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Semin Dial. 2000; 13 101-107
- 18 Miller E R, Alter M J, Tokars J I. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis. 1999; 33 356-360
- 19 Oddone E Z, Cowper P A, Hamilton J D, Feussner J R. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients. Health Serv Res. 1993; 28 97-121
- 20 Duarte R, Huraib S, Said R et al.. Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis. Am J Kidney Dis. 1995; 25 40-45
- 21 Rodrigues A, Morgado T, Areias J et al.. Limited benefits of INF-alpha therapy in renal graft candidates with chronic viral hepatitis B or C. Transplant Proc. 1997; 29 777-780
- 22 Fabrizi F, Lunghi G, Martin P. Recent advances in the management of hepatitis C in the dialysis population. Int J Artif Organs. 2002; 25 503-511
- 23 Ben-Ari Z, Broida E, Kittai Y, Chagnac A, Tur-Kaspa R. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. Am J Gastroenterol. 2000; 95 3579-3583
- 24 Boyacioglu S, Gur G, Gursoy M, Ozdemir N. Lamivudine in renal transplant candidates with chronic hepatitis B infection. Transplant Proc. 2002; 34 2131-2132
- 25 Schmilovitz-Weiss H, Melzer E, Tur-Kaspa R, Ben-Ari Z. Excellent outcome of lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastroenterol. 2003; 37 64-67
- 26 Fontaine H, Thiers V, Chretien Y et al.. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation. 2000; 69 2090-2094
- 27 Fabrizi F, Martin P, Ponticelli C. Hepatitis B virus and renal transplantation. Nephron. 2002; 90 241-251
- 28 Hiesse C, Buffer C, Neyrat N et al.. Impact of HBs antigenemia on long-term patient survival and causes of death after renal transplantation. Clin Transplant. 1992; 6 461-467
- 29 Mathurin P, Mouquet C, Poynard T et al.. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999; 29 257-263
- 30 Farza H, Salmon A M, Hadchouel M et al.. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice. Proc Natl Acad Sci USA. 1987; 84 1187-1191
- 31 Tur-Kaspa R, Burk R D, Shaul Y, Shafritz D A. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA. 1986; 83 1627-1631
- 32 McMillan J S, Shaw T, Angus P W, Locarnini S A. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology. 1995; 22 36-43
- 33 Cote C, Tennant B, Baldwin B, Korba B, Gerin J. Modulation of WHV Infection and Disease with Cyclosporine A and Dexamethasone. International Symposium on Viral Hepatitis and Liver Disease 1990
MissingFormLabel
- 34 Fornairon S, Pol S, Legendre C et al.. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation. 1996; 62 297-299
- 35 Rao K V, Kasiske B L, Anderson W R. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation. 1991; 51 391-396
- 36 Parfrey P S, Forbes R D, Hutchinson T A et al.. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation. 1985; 39 610-615
- 37 Grotz W, Gondolf K, Rasenack J et al.. Imminent liver failure in a hepatitis-B-positive renal-allograft recipient: successful therapy with interferon-alpha. Nephrol Dial Transplant. 1995; 10 1932-1934
- 38 Post A B, Hricik D E, Sterling R K et al.. Resolution of hepatitis B viremia in a renal transplant recipient treated with alpha-2b interferon. Nephron. 1998; 79 469-471
- 39 Kramer P, ten Kate F W, Bijnen A B, Jeekel J, Weimar W. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet. 1984; 1 989-990
- 40 Rostaing L, Modesto A, Baron E et al.. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron. 1996; 74 512-516
- 41 Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of HBV-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation. 2004; 77 859-864
- 42 Perrillo R P. Hepatitis B and renal transplantation: securing the sword of Damocles. Hepatology. 2002; 36 1041-1045
- 43 Fabrizi F, Lunghi G, Poordad F F, Martin P. Management of hepatitis B after renal transplantation: an update. J Nephrol. 2002; 15 113-122
- 44 Chan T M, Fang G X, Tang C S et al.. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002; 36 1246-1252
- 45 Schwarz A, Krause P H, Offermann G, Keller F. Impact of de novo membranous glomerulonephritis on the clinical course after kidney transplantation. Transplantation. 1994; 58 650-654
- 46 Rostaing L, Henry S, Cisterne J M et al.. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation. 1997; 64 1624-1627
- 47 Goffin E, Horsmans Y, Squifflet J P et al.. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients. Transplantation. 1999; 12 322-327
- 48 Hung Y O, Lee Y, Yang W S et al.. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Transplantation. 1998; 66 733-737
- 49 Kletzmayr J, Watschinger B, Muller C et al.. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation. 2000; 70 1404-1407
- 50 Tsai M K, Lai M Y, Hu R H et al.. Managing hepatitis B reactivation in renal transplant recipients: A 12-year review with emphasis on early detection and early use of lamivudine. Transplant Proc. 2000; 32 1935-1936
- 51 Lewandowska D, Durlik M, Kukula K et al.. Treatment of chronic hepatitis B with lamivudine in renal allograft recipients. Transplant Proc. 2000; 32 1369-1370
- 52 Antoine C, Landau A, Menoyo V et al.. Efficacy and safety of lamivudine in renal transplant patients with chronic hepatitis B. Transplant Proc. 2000; 32 384-385
- 53 Mouquet C, Bernard B, Poynard T et al.. Chronic hepatitis B treatment with lamivudine in kidney transplant patients. Transplant Proc. 2000; 32 2762
- 54 Lee W C, Wu M J, Cheng C H et al.. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis. 2001; 38 1074-1081
- 55 Han D J, Kim T H, Park S K et al.. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation. 2001; 71 387-394
- 56 Park S K, Yang W S, Lee Y S et al.. Outcome of renal transplantation in hepatitis B surface antigen-positive after introduction of lamivudine. Nephrol Dial Transplant. 2002; 16 2222-2228
- 57 Mosconi G, Scolari M P, Manna C et al.. Lamivudine in recurrent hepatitis B after renal transplantation. Transplant Proc. 2001; 33 1873-1874
Paul MartinM.D.
Center for Liver and Kidney Diseases and Transplantation, Cedars-Sinai Medical Center
8635 W. Third St., Suite 590W, Los Angeles, CA 90048
Email: martinpx@cshs.org